KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Treasury Shares (2019 - 2025)

Historic Treasury Shares for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $2.6 million.

  • Royalty Pharma's Treasury Shares fell 187.83% to $2.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.6 million, marking a year-over-year decrease of 187.83%. This contributed to the annual value of $2.6 million for FY2025, which is 187.83% down from last year.
  • As of Q4 2025, Royalty Pharma's Treasury Shares stood at $19.5 million, which was up 13206.0% from $20.5 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Treasury Shares ranged from a high of $21.5 million in Q2 2025 and a low of $3.1 million during Q2 2024
  • Moreover, its 3-year median value for Treasury Shares was $8.9 million (2023), whereas its average is $11.4 million.
  • As far as peak fluctuations go, Royalty Pharma's Treasury Shares surged by 2562.53% in 2021, and later tumbled by 630.79% in 2023.
  • Royalty Pharma's Treasury Shares (Quarter) stood at $2.7 million in 2021, then grew by 3.35% to $2.8 million in 2022, then decreased by 6.31% to $2.6 million in 2023, then increased by 1.26% to $2.7 million in 2024, then decreased by 1.88% to $2.6 million in 2025.
  • Its Treasury Shares stands at $2.6 million for Q4 2025, versus $2.6 million for Q3 2025 and $2.6 million for Q2 2025.